

## DAFTAR PUSTAKA

1. Kaseb H, Babiker HM. Hodgkin Lymphoma [Internet]. StatPearls Publisher; 2023 [dikutip 18 Januari 2024]. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK499969/>
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, dkk. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 4 Mei 2021;71(3):209–49.
3. GLOBOCAN (2022). Statistics at a glance, 2022 Top 5 most frequent cancers WHO SOUTH-EAST ASIA REGION (SEARO) [Internet]. 2022 [dikutip 16 Januari 2024]. Tersedia pada: <https://gco.iarc.who.int/media/globocan/factsheets/populations/995-who-south-east-asia-searo-fact-sheet.pdf>
4. GLOBOCAN. Cancer Today. Estimated number of new cases in 2022, Indonesia, both sexes, all ages [Internet]. 2022 [dikutip 16 Januari 2024]. Tersedia pada: <https://gco.iarc.fr/today/online-analysis-table?v=2020&>
5. Hasanah PF. Distribusi Frekuensi Limfoma Maligna Non-Hodgkin Di Laboratorium Patologi Anatomi Rs Dr. M. Djamil Padang Tahun 2020-2023. Universitas Andalas. 2024;
6. Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-Hodgkin's Lymphoma. Vol. 9, Medical sciences (Basel, Switzerland). NLM (Medline); 2021.
7. Kurnia B, Setiani L, Karnita Y, Berliananda I. Characteristics of non-Hodgkin lymphoma patients ORLI. Vol. 50. 2020.
8. Christine G, dkk. Rasio Neutrofil Limfosit sebagai Prediktor Neutropenia Akut Awitan Pertama Pascakemoterapi R-CHOP pada Pasien Diffuse Large B-cell Lymphoma Neutrophil Lymphocyte Ratio as A Predictor of The First Onset Acute Neutropenia After R-CHOP Chemotherapy in Diffuse Large B-cell Lymphoma Patients. Vol. 6, Jurnal Penyakit Dalam Indonesia |. 2019.
9. Gupta VK, Chaudhuri O. Mechanical regulation of cell-cycle progression and division. *Trends Cell Biol.* September 2022;32(9):773–85.
10. Setiati S, Alwi I, Sudoyo AW, Simadibrata K M, Setiyohadi B, Sudoyo AW, editor. Buku Ajar Ilmu Penyakit Dalam Jilid 1 Edisi 6. 6 ed. Vol. 1. Interna Publishing; 2015.
11. Febriani A, Rahmawati Y, Pulmonologi D, Ilmu D, Respirasi K, Kedokteran F, dkk. Efek Samping Hematologi Akibat Kemoterapi dan Tatalaksananya. Vol. 5. 2019.

12. Ogino MH, Tadi P. Cyclophosphamide. StatPearls Publishing [Internet]. 3 Juli 2023 [dikutip 12 April 2024]; Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK553087/>
13. Nabilah A, Cahyo Prabowo W, Kuncoro H. Pengaruh Kemoterapi terhadap Kadar Hematologi pada Pasien Kanker Payudara di RSUD dr. Kanujoso Djatiwibowo Balikpapan. *Jurnal Mandala Pharmacon Indonesia (JMPI)* [Internet]. 10(1):69–76. Tersedia pada: <https://doi.org/10.35311/jmpi>
14. Tara Audina N, Yusmawan W, Naftali Z. Perbandingan Kejadian Leukopenia Dan Trombositopenia Pada Pendertia Karsinoma Nasofaring Yang Mendapatkan Kemoterapi Paclitaxel Cisplatin Dan Cisplatin 5-Fluorouracil (5-FU). 2019;8(4).
15. Ayu Putri Miftahul Jannah. Perbedaan Kadar Leukosit Sebelum dan Sesudah Melakukan Kemoterapi pada Pasien Limfoma Non Hodgkin di RSU Haji Surabaya. Perpustakaan Universitas Airlangga. 2020;
16. Melani R, Darmawan E, Raharjo B. Gambaran Hubungan Regimen Dosis Dan Efek Samping Kemoterapi pada Pasien Kanker di RSUD Prof Dr. Margono Soekarjo Purwokerto Periode Bulan Januari-Februari Tahun 2019. *Majalah Farmaseutik*. 26 Agustus 2019;15(2):113.
17. Yelly Wulandari. Membandingkan Jumlah Dan Jenis Leukosit Pada Tahap Kemoterapi Terhadap Pasien Kanker Payudara Di Rs Dr. M. Djamil Padang. Program Studi Diploma Iv Analisis Kesehatan / Tlm Sekolah Tinggi Ilmu Kesehatan Perintis Padang. 2020;
18. Khairina A, Rosida A, KhairinaAlamat A. Tatalaksana Anemia Pada Nhl (Non Hodgkin Limfoma) Management of anemia in NHL (NonHodgkin lymphoma).
19. Fathia S, Syahrir M, Anastasia M, Bahar E. Pengaruh Pemberian Vitamin C Terhadap Kadar Serum LDH dan Kualitas Hidup Pasien Limfoma Non-Hodgkin. *Sriwijaya Journal of Medicine*. 4 Agustus 2021;4(2):123–30.
20. Sapkota S, Shaikh H. Non-Hodgkin Lymphoma. StatPearls Publishing [Internet]. 24 Februari 2023 [dikutip 20 Januari 2024]; Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK559328/>
21. Fikri Akbar A, Hasanah N, Pratiningrum M, Sawitri E. Usia Dan Jenis Kelamin Tidak Berhubungan Dengan Waktu Kekambuhan Pasien Limfoma Non-Hodgkin Pasca Kemoterapi Di Rsdul Abdul Wahab Sjahrane Samarinda. 2020.
22. Ludirdja EP, Rena NMRA, Suega K, Made Bakta I. Satu tahun kesintasan penderita limfoma non-hodgkin berdasarkan klasifikasi histopatologi working formulation. *Udayana Journal of Internal Medicine* [Internet]. 2018;2:28–31. Tersedia pada: [www.jpdonud.org](http://www.jpdonud.org)
23. Singh R, Shaik S, Negi B, Rajguru J, Patil P, Parihar A, dkk. Non-Hodgkin's lymphoma: A review. *J Family Med Prim Care*. 2020;9(4):1834.

24. Bowzyk Al-Naeeb A, Ajithkumar T, Behan S, Hodson DJ. Non-Hodgkin lymphoma. *BMJ (Online)*. 2018;362.
25. Chaudhari K, Rizvi S, Syed BA. Non-Hodgkin lymphoma therapy landscape. Vol. 18, *Nature Reviews Drug Discovery*. Nature Publishing Group; 2019. hlm. 663–4.
26. Fikri Akbar A, Hasanah N, Pratiningrum M, Sawitri E. Usia Dan Jenis Kelamin Tidak Berhubungan Dengan Waktu Kekambuhan Pasien Limfoma Non-Hodgkin Pasca Kemoterapi Di Rsud Abdul Wahab Sjahranie Samarinda.
27. Lecomte S, Demay F, Ferrière F, Pakdel F. Phytochemicals targeting estrogen receptors: Beneficial rather than adverse effects? Vol. 18, *International Journal of Molecular Sciences*. MDPI AG; 2017.
28. Patel GR, Prajapati GR. Clinical Spectrum And Subtype Distribution Of Non-Hodgkin's Lymphoma Based On The World Health Organization Classification Of Tumors Of Lymphoid Tissues (2017): An Analysis From A Tertiary Care Center In Western India. *World Cancer Research Journal*. 2023;10.
29. Singh R, Shaik S, Negi B, Rajguru J, Patil P, Parihar A, dkk. Non-Hodgkin's lymphoma: A review. *J Family Med Prim Care*. 2020;9(4):1834.
30. Komite Penanggulangan Kanker Nasional. Panduan Penatalaksanaan Limfoma Non-Hodgkin. 2017. 1–38 hlm.
31. R NS, Surarso B. Terapi Mual Muntah Pasca Kemoterapi. *Jurnal Tht - K1 Fakultas Kedokteran Universita Airlangga*. Mei 2016;9(2):74–83.
32. Soewoto W. 290P Use of PEG G-CSF is associated with decreased myelotoxicity in dexrazoxane-used aggressive non-Hodgkin lymphoma patients. *Annals of Oncology*. November 2022;33:S1544–5.
33. Jin H, Chen X, He W, Liu Q, Wei Z, Li J. Risk Factors for Chemotherapy-Induced Leukopenia in Patients with Lung Cancer. *Int J Clin Med*. 2016;07(03):225–30.
34. Subklewe M, Benjamin R. Management of Myelotoxicity (Aplasia) and Infectious Complications. Dalam: *The EBMT/EHA CAR-T Cell Handbook*. Springer International Publishing; 2022. hlm. 151–5.
35. Ningsih DR, Murwanti R, Nugroho AE. Pengaruh G-CSF Terhadap ANC Recovery pada Pasien Kanker dengan Neutropenia. *Media Ilmu Kesehatan*. 1 September 2023;12(2):185–93.
36. Parente J. Diagnostics for White Blood Cell Abnormalities: Leukocytosis and Leukopenia. Vol. 4, *Physician Assistant Clinics*. Elsevier Inc; 2019. hlm. 625–35.
37. Ryla C, Rk N, Mardina V. Pemeriksaan Jumlah Leukosit, Laju Endap Darah Dan Bakteri Tahan Asam (Bta) Pada Pasien Penyakit Tuberculosis Paru Di Rsud Langsa Evaluation Of Leukosit, Blood Rate And Bacterial Acid (Bta) In Patients Of Lung Tuberculosis Disease At Langsa Hospital. Vol. 1, *Biologica Samudra*. 2019.



38. Mohanty N, Kannan AN, Jain N. Clinical and hematological profile of pancytopenia in a tertiary care hospital of Southern Odisha, India. *Int J Res Med Sci.* 27 Maret 2019;7(4):1247.
39. Guyton AC, Hall JE. *Guyton and Hall Textbook of Medical Physiology.* 2014.
40. Sreenivas DS. Etiology of Pancytopenia in a Study in a Tertiary Care Hospital in North Andhra. *Journal of Medical Science And clinical Research [Internet].* 27 Agustus 2020;08(08). Tersedia pada: <http://jmscr.igmpublication.org/v8-i8/45%20jmscr.pdf>
41. Mart G, Malkan UY, Buyukasik Y. Determination of etiology in patients admitted due to isolated leukopenia. *Medicine (United States).* 19 Agustus 2022;101(33):E30116.
42. Parente J. Diagnostics for White Blood Cell Abnormalities: Leukocytosis and Leukopenia. Vol. 4, *Physician Assistant Clinics.* Elsevier Inc; 2019. hlm. 625–35.
43. Mahalingaiah PK, Palenski T, Van Vleet TR. An In Vitro Model of Hematotoxicity: Differentiation of Bone Marrow–Derived Stem/Progenitor Cells into Hematopoietic Lineages and Evaluation of Lineage-Specific Hematotoxicity. *Curr Protoc Toxicol.* 1 Mei 2018;76(1).
44. Tiana C, Hadi S, Purnomo FO. Hubungan Leukosit Dengan Glukosa Darah Pada Pasien Kaki Diabetik. *Binawan Student Journal.* 3(3).
45. Škubník J, Pavličková VS, Ruml T, Rimpelová S. Vincristine in combination therapy of cancer: Emerging trends in clinics. Vol. 10, *Biology.* MDPI; 2021.
46. Stork CM, Schreffler SM. Cyclophosphamide. Dalam: *Encyclopedia of Toxicology.* Elsevier; 2024. hlm. 417–21.
47. Kciuk M, Gielecińska A, Mujwar S, Kołat D, Kałuzińska-Kołat Ż, Celik I, dkk. Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity. Vol. 12, *Cells.* MDPI; 2023.
48. Nego A, Sebayang O. Efek Kardi toksik Obat Kemoterapi Doxorubicin. Vol. 7, *JIMKI.* 2019.
49. Zhang YW, Kong XY, Wang JH, Du GH. Natural Small Molecule Drugs from Plants: Vinblastine and Vincristine. Dalam: *Natural Small Molecule Drugs from Plants.* Springer Singapore; 2018. hlm. 551–62.
50. Puckett Y, Gabbar A, Bokhari AA. Prednisone: Mechanism of Action. *StatPearls Publishing.* 19 Juli 2023;
51. Tjandra L. Penggunaan Prednison Pada Penderita Asma Bronkhiale Dikaitkan Dengan Kadar Ige Dan Igg Penderita. 2022.
52. Yeni NP, Parastuti R, Made N, Rena RA. Gambaran Klinis Efek Samping Kemoterapi Pada Pasien Limfoma Maligna Yang Dirawat Di Rsup Sanglah

Denpasar Periode Januari 2015-Agustus 2016. Januari [Internet]. 2020;9(1):28–40. Tersedia pada: <https://ojs.unud.ac.id/index.php/eum>

53. Prof. Dr. Sugiyono. Metode Penelitian Kuantitatif, Kualitatif, Dan Rnd. 2014.
54. Departemen Kesehatan RI. Profil Kesehatan Indonesia. Departemen Republik Indonesia. 2009;
55. Ayu Cili Swesis I, Suega K, Made Renny Anggraeni Rena N. Kaitan Faktor Usia Dan Jenis Kelamin Terhadap Kejadian Limfoma Non Hodgkin Di Rumah Sakit Sanglah Tahun 2014. 2014.
56. Sari Y. Prevalensi dan Karakteristik Penderita Limfoma Maligna Selama 5 tahun di Bagian Patologi Anatomi RSUP Dr. Mohammad Hoesin Palembang. 2012;
57. Thieblemont C, Bernard S, Molina T. Management of aggressive lymphoma in very elderly patients. *Hematol Oncol*. 1 Juni 2017;35:49–53.
58. Yeni NP, Parastuti R, Made N, Rena RA. Gambaran Klinis Efek Samping Kemoterapi Pada Pasien Limfoma Maligna Yang Dirawat Di Rsup Sanglah Denpasar Periode Januari 2015-Agustus 2016. Januari [Internet]. 2020;9(1):28–40. Tersedia pada: <https://ojs.unud.ac.id/index.php/eum>
59. Fadhlia F, Kurnia B, Setiani L, Karnita Y, Juniar J, Berliananda I. Characteristics of non-Hodgkin lymphoma patients in Otorhinolaryngology-HNS Department Zainoel Abidin General Hospital Banda Aceh. *Oto Rhino Laryngologica Indonesiana*. 1 Juli 2020;50(1):46.
60. Cannavale K, Xu H, Xu L, Sattayapiwat O, Rodriguez R, Bohac C, dkk. Epidemiology of Chemotherapy-Induced Anemia in Patients with Non-Hodgkin Lymphoma. *Perm J*. September 2019;23(3).
61. Susanti WL, Nurrochmad A, Murwanti R. Perbandingan Kemoterapi Chop dan Rchop Terhadap Kejadian Anemia pada Pasien Kanker Limfoma Non-Hodgkin. | *Majalah Farmaseutik*. 2023;19(2):289–96.
62. Nabilah A, Cahyo Prabowo W, Kuncoro H. Pengaruh Kemoterapi terhadap Kadar Hematologi pada Pasien Kanker Payudara di RSUD dr. Kanujoso Djatiwibowo Balikpapan. *Jurnal Mandala Pharmacon Indonesia (JMPI)* [Internet]. 10(1):69–76. Tersedia pada: <https://doi.org/10.35311/jmpi>
63. Jahidin W, Noor Irfani F, Bagus Widyantara A, Kunci K, Payudara K, Darah Putih S. Nilai Tumor Marker CA 15-3 dan Kadar Leukosit Pada Penderita Kanker Payudara Yang Menjalani Kemoterapi Description Of Tumor Marker CA 15-3 and Leukocyte Levels In Breast Cancer Patients Undergoing Chemotherapy. Vol. 13, *Jurnal Analisis Kesehatan*. 2024.